Regenxbio Part I: A Novel Gene Therapy Innovator With Substantial Unlocked Value – Seeking Alpha
|
Regenxbio Part I: A Novel Gene Therapy Innovator With Substantial Unlocked Value
Seeking Alpha Notably, voretigene neparvovec-rzyl (Luxturna) – a one-time gene therapy for patients afflicted with biallelic RPE65 mutation-associated retinal dystrophy – of Sparks Therapeutics (NASDAQ:ONCE) was approved by the agency. While not a robust performe … |
